Cargando…
Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease
General lipid-lowering strategies exhibit clinical benefit, however, adverse effects and low adherence of relevant pharmacotherapies warrants the investigation into distinct avenues for preventing dyslipidemia-induced cardiovascular disease. Ion channels play an important role in the maintenance of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120415/ https://www.ncbi.nlm.nih.gov/pubmed/35600482 http://dx.doi.org/10.3389/fcvm.2022.876634 |
_version_ | 1784710919155089408 |
---|---|
author | Hudgins, Emma C. Bonar, Adam M. Nguyen, Thanh Fancher, Ibra S. |
author_facet | Hudgins, Emma C. Bonar, Adam M. Nguyen, Thanh Fancher, Ibra S. |
author_sort | Hudgins, Emma C. |
collection | PubMed |
description | General lipid-lowering strategies exhibit clinical benefit, however, adverse effects and low adherence of relevant pharmacotherapies warrants the investigation into distinct avenues for preventing dyslipidemia-induced cardiovascular disease. Ion channels play an important role in the maintenance of vascular tone, the impairment of which is a critical precursor to disease progression. Recent evidence suggests that the dysregulation of ion channel function in dyslipidemia is one of many contributors to the advancement of cardiovascular disease thus bringing to light a novel yet putative therapeutic avenue for preventing the progression of disease mechanisms. Increasing evidence suggests that lipid regulation of ion channels often occurs through direct binding of the lipid with the ion channel thereby creating a potential therapeutic target wherein preventing specific lipid-ion channel interactions, perhaps in combination with established lipid lowering therapies, may restore ion channel function and the proper control of vascular tone. Here we first detail specific examples of lipid-ion channel interactions that promote vascular dysfunction and highlight the benefits of preventing such interactions. We next discuss the putative therapeutic avenues, such as peptides, monoclonal antibodies, and aspects of nanomedicine that may be utilized to prevent pathological lipid-ion channel interactions. Finally, we discuss the experimental challenges with identifying lipid-ion channel interactions as well as the likely pitfalls with developing the aforementioned putative strategies. |
format | Online Article Text |
id | pubmed-9120415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91204152022-05-21 Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease Hudgins, Emma C. Bonar, Adam M. Nguyen, Thanh Fancher, Ibra S. Front Cardiovasc Med Cardiovascular Medicine General lipid-lowering strategies exhibit clinical benefit, however, adverse effects and low adherence of relevant pharmacotherapies warrants the investigation into distinct avenues for preventing dyslipidemia-induced cardiovascular disease. Ion channels play an important role in the maintenance of vascular tone, the impairment of which is a critical precursor to disease progression. Recent evidence suggests that the dysregulation of ion channel function in dyslipidemia is one of many contributors to the advancement of cardiovascular disease thus bringing to light a novel yet putative therapeutic avenue for preventing the progression of disease mechanisms. Increasing evidence suggests that lipid regulation of ion channels often occurs through direct binding of the lipid with the ion channel thereby creating a potential therapeutic target wherein preventing specific lipid-ion channel interactions, perhaps in combination with established lipid lowering therapies, may restore ion channel function and the proper control of vascular tone. Here we first detail specific examples of lipid-ion channel interactions that promote vascular dysfunction and highlight the benefits of preventing such interactions. We next discuss the putative therapeutic avenues, such as peptides, monoclonal antibodies, and aspects of nanomedicine that may be utilized to prevent pathological lipid-ion channel interactions. Finally, we discuss the experimental challenges with identifying lipid-ion channel interactions as well as the likely pitfalls with developing the aforementioned putative strategies. Frontiers Media S.A. 2022-05-06 /pmc/articles/PMC9120415/ /pubmed/35600482 http://dx.doi.org/10.3389/fcvm.2022.876634 Text en Copyright © 2022 Hudgins, Bonar, Nguyen and Fancher. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Hudgins, Emma C. Bonar, Adam M. Nguyen, Thanh Fancher, Ibra S. Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease |
title | Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease |
title_full | Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease |
title_fullStr | Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease |
title_full_unstemmed | Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease |
title_short | Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease |
title_sort | targeting lipid—ion channel interactions in cardiovascular disease |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120415/ https://www.ncbi.nlm.nih.gov/pubmed/35600482 http://dx.doi.org/10.3389/fcvm.2022.876634 |
work_keys_str_mv | AT hudginsemmac targetinglipidionchannelinteractionsincardiovasculardisease AT bonaradamm targetinglipidionchannelinteractionsincardiovasculardisease AT nguyenthanh targetinglipidionchannelinteractionsincardiovasculardisease AT fancheribras targetinglipidionchannelinteractionsincardiovasculardisease |